Benjamin Hudson

Benjamin Hudson

Auto-generated profile, based on publicly available information

Benjamin Hudson

University Hospitals Bristol NHS Foundation Trust, Bristol, UK

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Journal of Hepatology
Verified
Journal Article
Closed access
GFGraham R. Foster
Graham R. Foster
WIWilliam L. Irving
William L. Irving
MCMichelle C.M. Cheung
Michelle C.M. Cheung
AWAlex J. Walker
Alex J. Walker
BHBenjamin E. Hudson
Benjamin E. Hudson
KAKosh Agarwal
Kosh Agarwal

1 October 2016 in Journal of Hepatology
Verified
Journal Article
Open access
MCMichelle C.M. Cheung
Michelle C.M. Cheung
AWAlex J. Walker
Alex J. Walker
BHBenjamin E. Hudson
Benjamin E. Hudson
SVSuman Verma
Suman Verma
JMJohn McLauchlan
John McLauchlan
WIWilliam L. Irving
William L. Irving
Direct-acting antivirals have become widely used for patients with chronic hepatitis C virus infection with decompensated cirrhosis. Virological responses are excellent and early improvements in liver function, at least in a proportion of patients, have been observed but the longer term impact of viral clearance on end-stage liver disease complications is unclear. Prospective study of patients with decompensated cirrhosis who received 12weeks of all-oral direct-acting antivirals through the English Expanded Access Programme. Endpoints were deaths, liver transplantation, hepatocellular carcinoma, serious decompensation events, sepsis or hospitalisations, and MELD scores between start of therapy to 15months post-treatment start. An untreated cohort of patients was retrospectively studied over 6months for comparison. Amongst 317/406 patients who achieved sustained virological response at 24weeks post-treatment, there were 9 deaths (3%), 17 new liver cancers (5%), 39 transplantations (12%) and 52 with serious decompensations (16%), over 15months. When compared to the first six months from treatment start and to untreated patients, there was a reduction in incidence of decompensations [30/406 (7%) in months 6-15 and 72/406 (18%) in months 0-6 for treated patients vs. 73/261 (28%) in untreated patients]. There was no significant difference in liver cancer incidence (10/406 (2.5%) in months 6-15 and 17/406 (4%) in months 0-6 for treated patients vs. 11/261 (4%) in untreated patients). This study suggests that antiviral therapy in patients with decompensated cirrhosis led to prolonged improvement in liver function, with no evidence of paradoxical adverse impact nor increase in liver malignancy. This is a report of a large group of patients in England who have hepatitis C virus (HCV) infection with advanced liver disease. They have been treated with new anti-HCV drugs, which cured the infection in the majority. This study looks at their outcomes a year following treatment, in terms of deaths, cancers and other complications of advanced liver disease. We conclude that in most patients anti-HCV treatment is beneficial even in advanced liver disease.

1 February 2018 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
BHBenjamin Hudson
Benjamin Hudson
JRJeff Round
Jeff Round
BGBrendan Georgeson
Brendan Georgeson
APAndrew Pring
Andrew Pring
KFKaren Forbes
Karen Forbes
JVJulia Verne
Julia Verne

2 February 2018 in Palliative Medicine
Verified
Journal Article
Closed access
BHBenjamin Hudson
Benjamin Hudson
VHVictoria Hunt
Victoria Hunt
AWAndrea Waylen
Andrea Waylen
CMCatherine Anne McCune
Catherine Anne McCune
JVJulia Verne
Julia Verne
KFKaren Forbes
Karen Forbes
Background: Liver disease represents the third commonest cause of death in adults of working age and is associated with an extensive illness burden towards the end of life. Despite this, patients rarely receive palliative care and are unlikely to be involved in advance care planning discussions. Evidence addressing how existing services meet end-of-life needs, and exploring attitudes of patients and carers towards palliative care, is lacking. Aim: To explore the needs of patients and carers with liver disease towards the end of life, evaluate how existing services meet need, and examine patient and carer attitudes towards palliative care. Design: Qualitative study – semi-structured interviews analysed using thematic analysis. Settings/participants: A total of 17 participants (12 patients, 5 bereaved carers) recruited from University Hospitals Bristol. Results: Participants described escalating physical, psychological and social needs as liver disease progressed, including disabling symptoms, emotional distress and uncertainty, addiction, financial hardship and social isolation. End-of-life needs were incompatible with the healthcare services available to address them; these were heavily centred in secondary care, focussed on disease modification at the expense of symptom control and provided limited support after curative options were exhausted. Attitudes towards palliative care were mixed, however, participants valued opportunities to express future care preferences (particularly relating to avoidance of hospital admission towards the end of life) and an increased focus on symptomatic and logistical aspects of care. Conclusion: The needs of patients with liver disease and their carers are frequently incompatible with the healthcare services available to them towards the end of life. Novel strategies, which recognise the life-limiting nature of liver disease explicitly and improve coordination with community services, are required if end-of-life care is to improve.

5 October 2016 in Frontline Gastroenterology
Verified
Journal Article
Open access
PDF file
BHBenjamin E Hudson
Benjamin E Hudson
KAKelly Ameneshoa
Kelly Ameneshoa
AGAnya Gopfert
Anya Gopfert
RGRachael Goddard
Rachael Goddard
KFKaren Forbes
Karen Forbes
CMC Anne McCune
C Anne McCune
Background and objectives Patients with decompensated cirrhosis rarely receive palliative and supportive care interventions, which are routine in other life-limiting diseases. We aimed to design and evaluate a prognostic screening tool to routinely identify inpatients with decompensated cirrhosis at high risk of dying over the coming year, alongside the development of a supportive care intervention. Design Clinical notes from consecutive patients admitted as an emergency to University Hospitals Bristol with a diagnosis of cirrhosis over two distinct 90-day periods were scrutinised retrospectively for the presence or absence of five evidence-based factors associated with poor prognosis. These were analysed against their ability to predict mortality at 1 year. ‘Plan-Do-Study-Act’ (PDSA) methodology was used to incorporate poor-prognosis screening into the routine assessment of patients admitted with cirrhosis, and develop a supportive care intervention. Results 73 admissions were scrutinised (79.5% male, 63% alcohol-related liver disease, median age 54). The presence of three or more poor-prognosis criteria at admission predicted 1-year mortality with sensitivity, specificity and positive predictive value of 72.2%, 83.8% and 81.3%, respectively, and was used as a trigger for implementing the supportive care intervention. Following modification from six PDSA cycles, prognostic screening was integrated into the assessment of all patients admitted with decompensated cirrhosis, with the supportive care intervention (developed simultaneously) instigated for appropriate patients. Conclusions We describe a model of care which identifies inpatients with cirrhosis at significant risk of dying over the coming year, and describe development of a supportive care intervention, which can be offered to suitable patients in parallel to ongoing active management.

1 February 2006 in Ultrasound in Medicine & Biology
Verified
Journal Article
Closed access
SKSanjay Khanna
Sanjay Khanna
BHBenjamin Hudson
Benjamin Hudson
CPChristopher J. Pepper
Christopher J. Pepper
NANazar N. Amso
Nazar N. Amso
WCW. Terence Coakley
W. Terence Coakley